Immuno-humoral Rejection Markers in Pulmonary Transplant

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-02-28

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Open multicentric prospective study performed on pulmonary transplanted patients to detect the values of different diagnostic markers for immuno- humoral reaction and their roles in the humoral rejection for those patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bayesian Dose Adjustment of Immunosuppressants After Lung Transplantation

NCT00975663

Lung and Heart-lung Transplantation

TERMINATED PHASE4

BIOtechnology Applied to Renal TRansplantation With IMmunobiogram

NCT05816486

Kidney Transplant Failure and Rejection

COMPLETED

ALLoreactive T-Cell receptOr RePertoire in kidnEy tranSplantation

NCT03422224

Renal Transplant Rejection Immune Repertoire Transplant; Complication, Rejection +1 more

UNKNOWN

Randomized Controlled Trial of ImmuKnow in Liver Transplantation

NCT01764581

Liver Disease

COMPLETED NA

Noninvasive Methods to Monitor Graft Survival in Heart Transplant Patients

NCT00466804

Heart Transplant

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Transplant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulmonary transplant

Group Type EXPERIMENTAL

Blood test for detecting the circulatory anti-HLA antibodies by ELISA and LUMINEX tests

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood test for detecting the circulatory anti-HLA antibodies by ELISA and LUMINEX tests

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both genders, more than 18 years of age.
* Patients with or without Cystic fibrosis
* Patients with no previous unilateral or bilateral pulmonary transplant or cardiopulmonary transplant
* Patients with no current other disease can affect, in short term, the process or prognosis of the transplant
* Patients had given his agreement to be enrolled in the study

Exclusion Criteria

* Patient less than 18 year-old
* Patient had previous organ transplant
* Pregnant and/or lactating women
* Female subject in reproductive age does not use effective contraceptive methode
* Alcoholisms or neuropsychosis, conditions that affect the good comprehension of the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No